Epigenetic alterations, such as promoter hypermethylation of tumor suppressor genes (e.g., APC, TIMP3, CDH13), can serve as biomarkers to identify patients at higher risk of progression from BE to cancer. This evidence concerns the gene CDH13 and Barrett esophagus.